Jump to content

Miglustat

From Wikipedia, the free encyclopedia
Not to be confused with migalastat.

Miglustat
Clinical data
Trade namesZavesca, Brazaves, Opfolda
Other namesOGT 918, 1,5-(butylimino)-1,5-dideoxy-D-glucitol, N-butyl-deoxynojirimycin (NB-DNJ)
AHFS/Drugs.comMonograph
MedlinePlusa604015
License data
Pregnancy
category
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability97%
Protein bindingNil
MetabolismNil
Elimination half-life6–7 hours
ExcretionKidney, unchanged
Identifiers
  • (2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.216.074 Edit this at Wikidata
Chemical and physical data
FormulaC10H21NO4
Molar mass219.281 g·mol−1
3D model (JSmol)
  • OC[C@H]1N(CCCC)C[C@H](O)[C@@H](O)[C@@H]1O
  • InChI=1S/C10H21NO4/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3/t7-,8+,9-,10-/m1/s1 checkY
  • Key:UQRORFVVSGFNRO-UTINFBMNSA-N checkY
  (verify)

Miglustat, sold under the brand name Zavesca among others, is a medication used to treat type I Gaucher disease[7] and Pompe disease.[10]

It was approved for medical use in the European Union in November 2002,[7][11] and for medical use in the United States in July 2003.[12][13]

Medical uses

[edit]

Miglustat is indicated to treat adults with mild to moderate type I Gaucher disease for whom enzyme replacement therapy is unsuitable.[14]

In the European Union, miglustat (Opfolda), in combination with cipaglucosidase alfa, is a long-term enzyme replacement therapy in adults with late-onset Pompe disease (acid α‑glucosidase [GAA] deficiency).[10]

Contraindications

[edit]

Miglustat is contraindicated for people with neurological conditions, kidney problems, women who are pregnant, and men and women planning to conceive a child.[15]

Adverse effects

[edit]

Serious side effects include pain, burning, numbness or tingling in the hands, arms, legs, or feet; shaking hands that cannot be controlled; changes in vision; and easy bruising or bleeding. Common side effects include gastrointestinal effects (including diarrhea, stomach pain or bloating, gas, loss of appetite, weight loss, upset stomach, vomiting, constipation), dry mouth, muscular effects (including weakness, muscle cramps, especially in the legs, feeling of heaviness in the arms or legs, unsteadiness when walking), back pain, dizziness, nervousness, headache, memory problems, and difficult or irregular menstruation (period).[15]

Mechanism of action

[edit]

Type I Gaucher's disease is an autosomal recessive disorder; parents are generally healthy carriers with one functional and one mutated (nonfunctioning) copy of the Gaucher disease gene, GBA. People with type I Gaucher have a defect in the enzyme called glucocerebrosidase (also known as acid β-glucosidase). Glucocerebrosidase is an enzyme, and its function is to convert glucocerebroside (also known as glucosylceramide) into ceramide and glucose. When this enzyme doesn't work, glucocerebroside accumulates, which in turn causes liver and spleen enlargement, changes in the bone marrow and blood, and bone disease. Miglustat functions as a competitive and reversible inhibitor of the enzyme glucosylceramide synthase, the initial enzyme in a series of reactions which results in the synthesis of most glycosphingolipids.[16][17]

Earlier treatments on the market (imiglucerase (approved in 1995),[18] velaglucerase (approved in 2010),[19] taliglucerase alfa (Elelyso) (approved in 2012)[20]) are enzyme replacement therapy—they are functioning versions of the enzyme that doesn't work. Miglustat, on the other hand, prevents the formation of the substance that builds up when the enzyme doesn't work; this is called substrate reduction therapy.[21]

Chemistry

[edit]

Miglustat is an iminosugar, a synthetic analogue of D-glucose[22] and a white to off-white crystalline solid that has a bitter taste.[23]

Society and culture

[edit]
[edit]

Miglustat has been approved in the EU, Canada, and Japan for treating progressive neurological complications in people with Niemann–Pick disease, type C (NPC).[24][25][26][27][28]

On 26 April 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Opfolda, intended for the treatment of glycogen storage disease type II (Pompe disease) in combination with cipaglucosidase alfa.[10] The applicant for this medicinal product is Amicus Therapeutics Europe Limited.[10] Opfolda is a hybrid medicine of Zavesca which has been authorized in the EU since 2002.[10] Opfolda contains the same active substance as Zavesca but in a lower strength.[10] It is also authorized for a different indication and can only be used in combination with cipaglucosidase alfa.[10] Miglustat (Opfolda) was approved for medical use in the European Union in June 2023.[8][29]

Research

[edit]

In July 2004, Actelion started a clinical trial of miglustat to treat Tay–Sachs disease, particularly late-onset Tay–Sachs with an estimated enrollment of 10 subjects; the trial ended August 2007.[30]

In November 2007, Actelion initiated a clinical trial with miglustat in people with cystic fibrosis (CF) who have the ΔF508 in both copies of the cystic fibrosis transmembrane conductance regulator (CFTR) gene; the study ended in March 2008.[31] The cystic fibrosis trial showed no effect.[32]

N-butyldeoxynojirimycin interferes with the secretion of hepatitis B virus[33] and reduces the infectivity of HIV virions, in the latter case by preventing proper folding of the gp160 precursor glycoprotein to cause a conformational defect in mature gp120, which interferes with the process of fusion with host membranes.[34][35]

References

[edit]
  1. ^ "Miglustat (Zavesca) Use During Pregnancy". Drugs.com. 4 February 2020. Archived from the original on 28 November 2020. Retrieved 7 August 2020.
  2. ^ "Summary for ARTG Entry:122957 Zavesca miglustat 100 mg capsules blister pack". Therapeutic Goods Administration.[permanent dead link‍]
  3. ^ "Zavesca (miglustat) 100 mg hard capsules - Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 25 February 2021. Retrieved 7 August 2020.
  4. ^ "Zavesca- miglustat capsule". DailyMed. 20 April 2023. Retrieved 2 October 2023.
  5. ^ "Yargesa- miglustat capsule". DailyMed. 12 July 2023. Retrieved 2 October 2023.
  6. ^ https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215211s000lbl.pdf [bare URL PDF]
  7. ^ a b c "Zavesca EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 5 August 2020. Retrieved 7 August 2020.
  8. ^ a b "Opfolda EPAR". European Medicines Agency (EMA). 7 July 2023. Retrieved 7 July 2023.
  9. ^ "Yargesa EPAR". European Medicines Agency. 11 April 2023. Retrieved 2 October 2023.
  10. ^ a b c d e f g "Opfolda: Pending EC decision". European Medicines Agency. 26 April 2023. Archived from the original on 27 April 2023. Retrieved 27 April 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  11. ^ European Medicines Agency. Human Medicines Database. Zavesca (miglustat) Archived 7 January 2016 at the Wayback Machine Page Accessed 1 September 2014.
  12. ^ "Drug Approval Package: Zavesca (Miglustat) NDA #021348". U.S. Food and Drug Administration (FDA). 4 April 2002. Archived from the original on 27 February 2021. Retrieved 9 August 2020.
  13. ^ Actelion Press Release August 2003. Zavesca approved -- first oral treatment option for type 1 Gaucher disease Archived 3 March 2016 at the Wayback Machine
  14. ^ Cox TM, Aerts JM, Andria G, Beck M, Belmatoug N, Bembi B, et al. (2003). "The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement". Journal of Inherited Metabolic Disease. 26 (6): 513–526. doi:10.1023/a:1025902113005. PMID 14605497. S2CID 6681399.
  15. ^ a b American Society of Health-System Pharmacists, Inc. for the Public Library of Medicine. Miglustat on MedlinePlus Archived 5 July 2016 at the Wayback Machine Accessed 1 September 2014
  16. ^ Grabowski GA (2012). "Gaucher disease and other storage disorders". Hematology. American Society of Hematology. Education Program. 2012: 13–18. doi:10.1182/asheducation.v2012.1.13.3797921. PMID 23233555.
  17. ^ Huddleston RD (July 1999). "FDA Clinical Investigator Site Inspections: The Sponsor's Role". Drug Information Journal. 33 (3): 965–968. doi:10.1177/009286159903300338. ISSN 0092-8615. S2CID 72975032.
  18. ^ Deegan PB, Cox TM (2012). "Imiglucerase in the treatment of Gaucher disease: a history and perspective". Drug Design, Development and Therapy. 6: 81–106. doi:10.2147/DDDT.S14395. PMC 3340106. PMID 22563238.
  19. ^ "Shire Announces FDA Approval Of VPRIV(TM) (velaglucerase Alfa For Injection) For The Treatment Of Type I Gaucher Disease". Medicalnewstoday.com. Archived from the original on 13 June 2011. Retrieved 13 August 2012.
  20. ^ Yukhananov A (1 May 2012). "U.S. FDA approves Pfizer/Protalix drug for Gaucher". Chicago Tribune. Reuters. Retrieved 2 May 2012.[permanent dead link‍]
  21. ^ Actelion. FDA Advisory Briefing Book for Miglustat (Ogt 918, Zavesca) in Niemann-Pick Type C Disease NDA 021-348/S-007 Archived 9 May 2017 at the Wayback Machine Prepared for the Endocrinologic and Metabolic Drugs Advisory Committee meeting, 1 December 2009
  22. ^ Abian O, Alfonso P, Velazquez-Campoy A, Giraldo P, Pocovi M, Sancho J (December 2011). "Therapeutic strategies for Gaucher disease: miglustat (NB-DNJ) as a pharmacological chaperone for glucocerebrosidase and the different thermostability of velaglucerase alfa and imiglucerase". Molecular Pharmaceutics. 8 (6): 2390–2397. doi:10.1021/mp200313e. PMID 21988669.
  23. ^ European Medicines Agency 1 April 2003 Scientific discussion related to approval of Zavesca Archived 24 September 2015 at the Wayback Machine.
  24. ^ UK Medicines Information. New Drugs Online Report for miglustat Archived 4 March 2016 at the Wayback Machine
  25. ^ Staff, The Pharma Letter. 4 April 2012. Actelion drops setipiprant, gets miglustat approval in Japan Archived 31 October 2018 at the Wayback Machine
  26. ^ Kevin Grogan for PharmaTimes. 10 March 2010. FDA rejects Actelion's Zavesca for rare NP-C disease Archived 3 September 2014 at the Wayback Machine
  27. ^ Actelion Press Release. 23 March 2010 Zavesca (Miglustat) First Treatment Available in Canada for Rare Progressive Niemann-Pick Type C Disease Archived 17 May 2017 at the Wayback Machine
  28. ^ Solomon BI, Smith AC, Sinaii N, Farhat N, King MC, Machielse L, et al. (December 2020). "Association of Miglustat With Swallowing Outcomes in Niemann-Pick Disease, Type C1". JAMA Neurology. 77 (12): 1564–1568. doi:10.1001/jamaneurol.2020.3241. PMC 7489403. PMID 32897301.
  29. ^ "Opfolda Product information". Union Register of medicinal products. 27 June 2023. Archived from the original on 28 June 2023. Retrieved 3 July 2023.
  30. ^ Clinical trial number NCT00672022 for "Pharmacokinetics, Safety and Tolerability of Zavesca (Miglustat) in Patients With Infantile Onset Gangliosidosis: Single and Steady State Oral Doses" at ClinicalTrials.gov
  31. ^ Clinical trial number NCT00537602 for "OGT 918 in the Treatment of Cystic Fibrosis" at ClinicalTrials.gov
  32. ^ Leonard A, Lebecque P, Dingemanse J, Leal T (May 2012). "A randomized placebo-controlled trial of miglustat in cystic fibrosis based on nasal potential difference". Journal of Cystic Fibrosis. 11 (3): 231–236. doi:10.1016/j.jcf.2011.12.004. PMID 22281182.
  33. ^ Block TM, Lu X, Platt FM, Foster GR, Gerlich WH, Blumberg BS, et al. (March 1994). "Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin". Proceedings of the National Academy of Sciences of the United States of America. 91 (6): 2235–2239. Bibcode:1994PNAS...91.2235B. doi:10.1073/pnas.91.6.2235. PMC 43345. PMID 8134380.
  34. ^ Fischer PB, Karlsson GB, Butters TD, Dwek RA, Platt FM (October 1996). "N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with changes in antibody recognition of the V1/V2 region of gp120". Journal of Virology. 70 (10): 7143–7152. doi:10.1128/JVI.70.10.7143-7152.1996. PMC 190767. PMID 8794361.
  35. ^ Pollock S, Dwek RA, Burton DR, Zitzmann N (October 2008). "N-Butyldeoxynojirimycin is a broadly effective anti-HIV therapy significantly enhanced by targeted liposome delivery". AIDS. 22 (15): 1961–1969. doi:10.1097/QAD.0b013e32830efd96. PMID 18753929.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Miglustat&oldid=1264799463"